Prostate cancer drugs market is expected to reach US$ 28.10 Billion by 2033 | Astellas Pharma, Pfizer Inc, Bayer, Novartis, AstraZeneca and Sanofi

Global prostate cancer drugs market size was US$ 13.22 Billion in 2024 is expected to reach US$ 28.10 Billion by 2033 growing at a CAGR of 8.1% during the forecast period 2025-2033.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/prostate-cancer-drugs-market?sg

Key 2025 Developments & Drug Advances in Prostate Cancer:

✅ 2025‐03‐05: HLD-0915 - an investigational oral small‐molecule therapy from Halda Therapeutics - dosed its first patient in a Phase 1/2 trial for metastatic castration‐resistant prostate cancer (mCRPC), marking the official start of human testing.

✅ 2025‐08‐14: HLD-0915 received a "Fast Track" designation from the U.S. Food and Drug Administration (FDA) for mCRPC - a regulatory step intended to accelerate development and review, reflecting its potential as a meaningful new therapy.

✅ 2025‐10‐24 to 2025‐11‐17: The global giant Johnson & Johnson (J&J) agreed to acquire Halda Therapeutics for US $3.05 billion - a major M&A deal in oncology. The acquisition underscores J&J's commitment to expand its oncology portfolio, including novel prostate cancer therapies.

✅ 2025 (various): Halda - now under J&J - reported early clinical data from HLD-0915 showing encouraging safety, tolerability and antitumor activity (tumor shrinkage, PSA declines) in heavily pretreated prostate cancer patients.

✅ 2025‐06 (midyear): The darolutamide (brand name Nubeqa) - an androgen receptor inhibitor - plus standard androgen‐deprivation therapy (ADT) obtained expanded regulatory approval (in the UK) by the Medicines and Healthcare products Regulatory Agency (MHRA) as a treatment for metastatic hormone‐sensitive prostate cancer (mHSPC).

Regional share & dynamics:

➠ North America - market leader: Largest revenue share driven by high diagnosis rates, strong reimbursement, rapid uptake of novel therapies, and concentrated payer coverage for advanced drugs. Expect North America to remain the dominant region in near term. (Cited sources show North America as the top region.)

➠ Europe - fast follower / high growth: Rapid uptake of new indications (EMA approvals, label expansions such as darolutamide filings) and supportive clinical adoption make Europe a fast-growing market. Pricing and HTA processes influence roll-out timing country-by-country.

➠ Asia-Pacific - meaningful share & rising fastest in some segments: APAC accounted for roughly ~21-22% of revenues in some datasets (2024); growth is driven by expanding diagnostics, improved treatment access, and rising incidence (China, Japan, South Korea, Australia). However, absolute per-patient spend remains lower than North America/Europe, so growth depends on reimbursement expansion and local approvals.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/prostate-cancer-drugs-market?sg

Key growth drivers:

✅ New targeted therapies and oral agents - next-gen androgen receptor inhibitors (enzalutamide, apalutamide, darolutamide and follow-ons) and oral hormonal agents are replacing older options and expanding treatment lines. Regulatory label expansions and combination approvals raise addressable patient populations.

✅ PARP inhibitors and precision oncology - approvals and trial successes for PARP inhibitors in biomarker-positive prostate cancer (BRCA/PARP-sensitive tumors) are creating new therapy classes and higher-value treatment options.

✅ PSMA-targeted radioligand therapy & theranostics - PSMA agents (therapeutic + diagnostic pairings) are a major structural market driver, bringing imaging-linked revenue and higher per-patient lifetime spend. Datamintelligence and other reports explicitly flag PSMA radiotherapies as a reshaping factor.

✅ Rising incidence, screening and earlier diagnosis - increasing detection and longer survivorship lead to greater cumulative treatment exposure per patient (more lines of therapy over longer periods).

✅ Long-acting formulations & adherence improvements - depot injections and less frequent dosing improve adherence and shift product preference, supporting higher market uptake.

Segments Covered in the Prostate Cancer Drugs Market:

By Therapy Type (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy.)

By Route of Administration (Oral, Intravenous, Others)

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Regional Analysis for Prostate Cancer Drugs Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=prostate-cancer-drugs-market?sg

Major Key Players: Astellas Pharma, Pfizer Inc, Johnson & Johnson (Janssen Biotech, U.S.), Bayer, Novartis, AstraZeneca and Sanofi.

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Prostate Cancer Drugs market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Prostate Cancer Drugs Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Prostate Cancer Drugs market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Prostate Cancer Drugs Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription?sg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.